OT-404, multi-targeted anti-cancer agent affecting tumor proliferation, chemo-resistance, and angiogenesis
No Thumbnail Available
Date
2013-05
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Abstract
There is a need for a comprehensive anti-cancer strategy that simultaneously targets abnormal proliferation, angiogenesis rates, and development of chemotherapy resistance. We have identified a small molecule, OT-404, that effectively inhibited proliferation and angiogenesis of either chemo-sensitive or resistant human cancer cells and enhanced cancer cell sensitivity to different chemotherapy. In vivo studies of human tumor xenografts in nude mice showed that OT-404, used alone or encapsulated into nanoparticles, inhibited the growth of doxorubicin-resistant breast cancer MCF-7 by more than 80%, and by 95% when combined with doxorubicin. These findings provide evidence for the potential of OT-404 in cancer management.
Description
Keywords
Oncology, Angiogenesis, Chemo-resistance, Nanoparticles, OT-404, Hormone-releasing-hormone, Endothelial growth-factor, Thyroid-hormone, Prongiogenic action, Kinase inhibitor, Tyrosine kinase, Down-regülation, Cancer-therapy, Phase-II, In-vivo, Mus musculus
Citation
Rebbaa, A. vd. (2013). “OT-404, multi-targeted anti-cancer agent affecting tumor proliferation, chemo-resistance, and angiogenesis”. Cancer Letters, 332(1), 55-62.